Computational Modeling vs. the High Cost and Failure Rate of Drug Development
Computational modeling is becoming a practical way to shift part of drug development risk from patients into transparent, in silico environments. By combining tools like virtual screening, PK/PD, QSP, and in silico clinical trials, teams can explore dose, mechanism, variability, and trial design before exposing thousands of participants—cutting low-value compounds early and sharpening late-stage decisions. It doesn’t replace clinical trials, but it directly tackles the core problem of poor prediction, helping ensure that the drugs reaching Phase III are the ones most likely to work.